Five talking points
From the latest edition of each brief.
Biotech & Pharma Intelligence
- A second pan-RAS drug, Erasca’s ERAS-0015, reports responses in pancreatic cancer, from a small Phase 1 with no control group. Claim
- Daraxonrasib plus chemotherapy reached a 60.7% response rate first line in 61 patients; the randomized test is still to come. Claim
- Actinogen’s Xanamem missed its pivotal Alzheimer’s primary; the company now points to older patients. Claim
- An RNAi drug dosed four times a year is now approved for generalized myasthenia gravis, per Alnylam. Claim
- Sanofi’s reported interest in Insmed is a press report, not an announced deal. Analysis
AI & Technology Intelligence
- The suppliers fell hardest. Chips fell about 10%; the cloud buyers fell 2.56% to 5.82%.
- Seven drivers, none settled. Every one we tested has evidence; none is shown as the cause.
- Anthropic’s deal is done. About $119.5 billion combined, and the stock is still above $83.
- China exposure is the new question. A committee release and a short report are claims, not findings.
- The operating system may decide. Biotech & pharma If Apple limits outside agents, check which tools your teams rely on.

